75
Participants
Start Date
October 23, 2023
Primary Completion Date
February 28, 2026
Study Completion Date
March 31, 2026
Teclistamab
Teclistamab will be administered subcutaneously at step-up doses on Day 1, Day 4 and Day 8, one week after first treatment dose and weekly thereafter. In participants who have a partial response (PR) or better after 6 months of therapy, dosing frequency may be reduced to every 2 weeks.
Talquetamab
Talquetamab will be administered subcutaneously at step-up doses on Day 1, Day 4, Day 8 and Day 15, one week after first treatment dose and every 2 weeks thereafter. In participants who have a very good partial response (VGPR) or better after Cycle 4, dosing frequency may be reduced to every 4 weeks
Tocilizumab
Tocilizumab will be administered as a pretreatment medication in advance of administration of the first step-up dose of teclistamab or talquetamab on Cycle 1 Day 1.
RECRUITING
Medical Oncology Hematology Consultants, Newark
RECRUITING
Maryland Oncology Hematology, Columbia
RECRUITING
Virginia Cancer Specialists, Fairfax
RECRUITING
Virginia Oncology Associates, Norfolk
RECRUITING
Blue Ridge Cancer Center, Roanoke
RECRUITING
Florida Cancer Specialists, Lake Mary
RECRUITING
TriStar Bone Marrow Transplant, Nashville
RECRUITING
Oncology Hematology Care, Cincinnati
RECRUITING
Minnesota Oncology Hematology, Minneapolis
RECRUITING
Texas Oncology - Northeast Texas, Tyler
RECRUITING
Texas Oncology - San Antonio, San Antonio
RECRUITING
Texas Oncology, Austin
RECRUITING
Colorado Blood Cancer Institute, Denver
RECRUITING
Rocky Mountain Cancer Center, Denver
RECRUITING
Arizona Oncology Associates, Tucson
RECRUITING
Oncology Associates of Oregon, Eugene
Collaborators (1)
Johnson & Johnson
INDUSTRY
SCRI Development Innovations, LLC
OTHER